Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. (Q30372260)

21 June 2017

title

Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. (English)

1 reference

21 June 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Frieke Kuper

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Sandrine Wouters

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Danielle Morelle

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gaëlle Gautier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Julien Le Gal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Thomas Martin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Eric Destexhe

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Arnaud M Didierlaurent

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Nathalie Garçon

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

27 February 2015

1 reference

Journal of Applied Toxicology

21 June 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1564-1576

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

4 June 2020

cites work

1 reference

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

21 January 2018

1 reference

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.

21 January 2018

1 reference

Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins

21 January 2018

1 reference

Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway

21 January 2018

1 reference

Influenza vaccine immunology

21 January 2018

1 reference

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.

21 January 2018

1 reference

Acute-phase proteins and other systemic responses to inflammation

21 January 2018

1 reference

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

21 January 2018

1 reference

Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges

21 January 2018

1 reference

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons

21 January 2018

1 reference

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

21 January 2018

1 reference

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

21 January 2018

1 reference

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

21 January 2018

1 reference

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

21 January 2018

1 reference

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

Prediction and prevention of the next pandemic zoonosis

21 January 2018

1 reference

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

21 January 2018

1 reference

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

21 January 2018

1 reference

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

21 January 2018

1 reference

H5N1 influenza--continuing evolution and spread

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JAT.3130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25727696%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference